The increasing global demand for obesity drugs, particularly GLP-1 medications, is driving Indian pharmaceutical companies to seek licensing and distribution partnerships. Experts anticipate a surge in such deals as patents expire, opening opportunities for Indian firms to enter the lucrative market. Companies are forming collaborations for manufacturing, supply chain, and distribution, including agreements for novel GLP-1 drugs and generic versions, aiming to capture a larger market share.